Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling

• Published in: American journal of respiratory and critical care medicine 2016-03, Vol.193 (5), p.542-551
• Main Authors: Wille, Mathilde M W, Dirksen, Asger, Ashraf, Haseem, Saghir, Zaigham, Bach, Karen S, Brodersen, John, Clementsen, Paul F, Hansen, Hanne, Larsen, Klaus R, Mortensen, Jann, Rasmussen, Jakob F, Seersholm, Niels, Skov, Birgit G, Thomsen, Laura H, Tønnesen, Philip, Pedersen, Jesper H
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - diagnostic imaging; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Aged; Carcinoma, Non-Small-Cell Lung - diagnostic imaging; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Squamous Cell - diagnostic imaging; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - pathology; Comorbidity; Denmark - epidemiology; Early Detection of Cancer; Female; Humans; Lung - diagnostic imaging; Lung - pathology; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Middle Aged; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive - epidemiology; Risk Assessment; Small Cell Lung Carcinoma - diagnostic imaging; Small Cell Lung Carcinoma - mortality; Small Cell Lung Carcinoma - pathology; Smoking; Tomography, X-Ray Computed
• ISSN: 1073-449X; 1535-4970
• DOI: 10.1164/rccm.201505-1040OC

As of April 2015, participants in the Danish Lung Cancer Screening Trial had been followed for at least 5 years since their last screening. Mortality, causes of death, and lung cancer findings are reported to explore the effect of computed tomography (CT) screening. A total of 4,104 participants aged 50-70 years at the time of inclusion and with a minimum 20 pack-years of smoking were randomized to have five annual low-dose CT scans (study group) or no screening (control group). Follow-up information regarding date and cause of death, lung cancer diagnosis, cancer stage, and histology was obtained from national registries. No differences between the two groups in lung cancer mortality (hazard ratio, 1.03; 95% confidence interval, 0.66-1.6; P = 0.888) or all-cause mortality (hazard ratio, 1.02; 95% confidence interval, 0.82-1.27; P = 0.867) were observed. More cancers were found in the screening group than in the no-screening group (100 vs. 53, respectively; P < 0.001), particularly adenocarcinomas (58 vs. 18, respectively; P < 0.001). More early-stage cancers (stages I and II, 54 vs. 10, respectively; P < 0.001) and stage IIIa cancers (15 vs. 3, respectively; P = 0.009) were found in the screening group than in the control group. Stage IV cancers were nonsignificantly more frequent in the control group than in the screening group (32 vs. 23, respectively; P = 0.278). For the highest-stage cancers (T4N3M1, 21 vs. 8, respectively; P = 0.025), this difference was statistically significant, indicating an absolute stage shift. Older participants, those with chronic obstructive pulmonary disease, and those with more than 35 pack-years of smoking had a significantly increased risk of death due to lung cancer, with nonsignificantly fewer deaths in the screening group. No statistically significant effects of CT screening on lung cancer mortality were found, but the results of post hoc high-risk subgroup analyses showed nonsignificant trends that seem to be in good agreement with the results of the National Lung Screening Trial. Clinical trial registered with www.clinicaltrials.gov (NCT00496977).